Tradestie Institutional Equity Comparison Engine · Market Close Nov 19, 2026

TNDM vs KIDS: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

TNDM Wins Head-to-Head Institutional Verdict (3–3 across 6 Pillars · 4–4 Matrix Metrics)

TNDM Overall Winner 6-Pillar Tally: TNDM 3 – 3 KIDS Matrix Metrics: TNDM 4 – 4 KIDS

As of Nov 19, 2026, Tandem Diabetes Care, Inc. (TNDM) is the stronger overall head-to-head candidate over OrthoPediatrics Corp. (KIDS) in the Tradestie Institutional Equity Comparison Engine, winning 4–4 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Options & Positioning). TNDM carries a Unified Composite Score of 30.8/100 (SELL) at $16.80 (N/M Forward P/E, -2.4% operating margin), whereas KIDS carries 45.1/100 (HOLD) at $32.51 (N/M Forward P/E, -8.2% operating margin).

  • Composite vs. Pillar Nuance: While KIDS currently prints a higher short-term Unified Composite Score (45.1/100 HOLD vs. TNDM 30.8/100 SELL), TNDM captures the overall institutional head-to-head verdict (4–4 matrix metrics and 3–3 across the 6 pillars) due to superior fundamental profitability (-2.4% vs. -8.2% operating margin) and revenue trajectory (+13.8% vs. +18.6% YoY).
  • Technical & Structure Timing Caution: TNDM is currently in a Weinstein Distribution regime near a flattening 50-day moving average and Breakdown options structure phase (RSI 44.6); meanwhile KIDS trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 64.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About TNDM vs KIDS
TNDM NASDAQ Head-to-Head Winner
Tandem Diabetes Care, Inc.
Surgical & Medical Instruments & Apparatus
$16.80
-1.47% 1D
Market Cap $1.2B
TTM Revenue $1.08B
Forward P/E N/M
Beta / 30D Vol 1.21β · 94% Vol
Unified Composite Score
30.8 / 100 SELL
Tech 20.0 Fund 37.0 Flow 69.0 Mom 11.1
Weinstein Technical Phase Distribution · Trim / tighten stop
Price near a flattening SMA50 (slope -6.8%) with fading momentum, RSI 45
RSI-14: 44.6 · SMA20: $18.35 · SMA50: $17.24
KIDS NASDAQ
OrthoPediatrics Corp. Common Stock
Surgical & Medical Instruments & Apparatus
$32.51
+2.72% 1D
Market Cap $850.2M
TTM Revenue $264M
Forward P/E N/M
Beta / 30D Vol 0.81β · 108% Vol
Unified Composite Score
45.1 / 100 HOLD
Tech 28.0 Fund 40.0 Flow 50.0 Mom 46.3
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (12.1% over 20 days), RSI 64
RSI-14: 64.2 · SMA20: $30.90 · SMA50: $25.86

6-Pillar Scorecard Institutional Category Breakdown (TNDM 3 – 3 KIDS)

Columns: Metric · TNDM · KIDS
1. Valuation Multiples TNDM
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue 1.7x 3.2x
2. Growth & Scale KIDS
Revenue Growth (YoY) +13.8% +18.6%
Earnings Growth (YoY) -37.0% +0.0%
TTM Revenue (USD) $1.08B $264M
Market Cap $1.2B $850.2M
3. Profitability & Quality TNDM
Gross Margin 56.6% 73.8%
Operating Margin -2.4% -8.2%
Net Profit Margin -4.6% -12.8%
Return on Equity (ROE) -36.7% -9.8%
4. Balance Sheet & Cash Flow KIDS
Cash Generation (TTM) -$71M $1.1M EBITDA
Cash Flow Margin -6.6% 0.4% EBITDA Mgn
Net Cash / Leverage $664M Net Debt (5.45x D/E) $12.99 Book/Sh · -9.8% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning TNDM
Options Structure Phase BREAKDOWN UNCLASSIFIED
Current IV / %ile 193.7% (45th %ile) 145.1% (100th %ile)
Put/Call OI Skew 0.45x (Call-Skewed) N/A
OBV Trend / Tech Phase ACCUMULATION · Distribution NEUTRAL · Markup
6. R&D & Supply-Chain Moat KIDS
OpEx & R&D Intensity 59.0% of Rev ($635M) 82.0% of Rev ($217M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Medical Devices Operator Medical Devices Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: TNDM (4) vs KIDS (4)
Institutional Metric TNDM KIDS Criterion Row Edge
Market Capitalization
Scale
$1.2B $850.2M Larger Scale TNDM
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+13.8% +18.6% Higher Growth KIDS
Operating Margin (TTM)
Profitability
-2.4% -8.2% Higher Margin TNDM
Net Profit Margin
Profitability
-4.6% -12.8% Higher Margin TNDM
Return on Equity (ROE)
Capital Efficiency
-36.7% -9.8% Higher ROE KIDS
52-Week Range Position
Momentum
26% ($12–$30) 90% ($14–$35) Stronger Trend KIDS
Beta / 30D Volatility
Risk Regime
1.21β · 94% Vol 0.81β · 108% Vol Lower Realized Risk TNDM
Unified Institutional Score
Composite Signal
30.8 / 100 (SELL) 45.1 / 100 (HOLD) Higher Composite KIDS
Trailing 12M Revenue (USD)
Operating Scale
$1.08B $264M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
56.6% 73.8% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 1.7x EV/Rev N/M PEG · 3.2x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$71M ($664M Net Debt (5.45x D/E)) $1.1M EBITDA ($12.99 Book/Sh · -9.8% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon KIDS +33.62 pp
TNDM: +2.75% · KIDS: +36.37%
3M Horizon KIDS +51.47 pp
TNDM: -24.73% · KIDS: +26.74%
6M Horizon KIDS +69.8 pp
TNDM: +6.6% · KIDS: +76.4%
1Y Horizon KIDS +109.05 pp
TNDM: -10.21% · KIDS: +98.84%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on TNDM vs KIDS. Trailing 12-month operating profitability (TNDM -2.4% vs KIDS -8.2%) and valuation multiples (TNDM N/M vs KIDS N/M Forward P/E) are benchmarked directly in Pillar 4 below.

TNDM ADR TTM Benchmark FX-Normalized USD
TTM Revenue$1.08B
Gross Margin56.6%
Op. Margin-2.4%
ROE / Fwd P/E-36.7% · N/M
KIDS ADR TTM Benchmark FX-Normalized USD
TTM Revenue$264M
Gross Margin73.8%
Op. Margin-8.2%
ROE / Fwd P/E-9.8% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
TNDM BREAKDOWN
71d in phase · OBV ACCUMULATION
Current IV 193.7%
IV Percentile 45th %ile
Put/Call OI Skew 0.45x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact TNDM Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
KIDS UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 145.1%
IV Percentile 100th %ile
Put/Call OI Skew N/A
IV Regime Extreme (>80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact KIDS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
TNDM Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $1.2B market capitalization and -2.4% operating margin.
OpEx & R&D Reinvestment 59.0% of Rev ($635M)
90D Engineering Disclosures 0 Published
KIDS Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $850.2M market capitalization and -8.2% operating margin.
OpEx & R&D Reinvestment 82.0% of Rev ($217M)
90D Engineering Disclosures 0 Published

Investor FAQ TNDM vs KIDS Key Questions & Quantitative Answers

As of Nov 19, 2026, Tandem Diabetes Care, Inc. (TNDM) is the stronger overall head-to-head candidate over OrthoPediatrics Corp. (KIDS) in the Tradestie Institutional Equity Comparison Engine, winning 4–4 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Options & Positioning). TNDM carries a Unified Composite Score of 30.8/100 (SELL) at $16.80 (N/M Forward P/E, -2.4% operating margin), whereas KIDS carries 45.1/100 (HOLD) at $32.51 (N/M Forward P/E, -8.2% operating margin). Composite vs. Pillar Nuance: While KIDS currently prints a higher short-term Unified Composite Score (45.1/100 HOLD vs. TNDM 30.8/100 SELL), TNDM captures the overall institutional head-to-head verdict (4–4 matrix metrics and 3–3 across the 6 pillars) due to superior fundamental profitability (-2.4% vs. -8.2% operating margin) and revenue trajectory (+13.8% vs. +18.6% YoY). Technical & Structure Timing Caution: TNDM is currently in a Weinstein Distribution regime near a flattening 50-day moving average and Breakdown options structure phase (RSI 44.6); meanwhile KIDS trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 64.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

KIDS leads the Growth & Scale pillar: TNDM posts +13.8% YoY revenue growth and -37.0% YoY earnings growth on $1.08B TTM revenue (56.6% gross margin, -2.4% operating margin), compared with KIDS at +18.6% YoY revenue growth and +0.0% YoY earnings growth on $264M TTM revenue (73.8% gross margin, -8.2% operating margin). On trailing 12-month operating scale, TNDM generates $1.08B in USD-normalized revenue versus $264M for KIDS. In operating R&D and SG&A reinvestment, TNDM deploys 59.0% of Rev ($635M) (0 90-day corporate R&D disclosures) versus 82.0% of Rev ($217M) (0 disclosures) for KIDS.

TNDM screens cheaper on headline valuation multiples. TNDM trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 1.7x EV/Revenue (-6.6% FCF margin), whereas KIDS trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 3.2x EV/Revenue (0.4% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against TNDM (-36.7% ROE) versus KIDS (-9.8% ROE) capital efficiency.

In options market volatility and institutional positioning, TNDM carries 193.7% implied volatility (45th %ile, Balanced (25th–60th %ile)), a 0.45x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a BREAKDOWN options structure phase (1.21β · 94% Vol realized risk). By comparison, KIDS carries 145.1% implied volatility (100th %ile, Extreme (>80th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.81β · 108% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 19, 2026. For educational research only; not investment advice.